T. Rowe Price Associates
MYOV

T. Rowe Price Associates’s Myovant Sciences Ltd. MYOV Stock Holding History

T. Rowe Price Associates’s Portfolio MYOV Stock Details MYOV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-10,900
Closed -$294K – 2982
2022
Q4 		$294K Hold
10,900
– – ﹤0.01% 2379
2022
Q3 		$196K Hold
10,900
– – ﹤0.01% 2553
2022
Q2 		$135K Hold
10,900
– – ﹤0.01% 2693
2022
Q1 		$145K Hold
10,900
– – ﹤0.01% 2781
2021
Q4 		$170K Buy
+10,900
New +$208K ﹤0.01% 2793
2019
Q4 		– Sell
-613,315
Closed -$3.19M – 2562
2019
Q3 		$3.19M Sell
613,315
-473,578
-44% -$3.51M ﹤0.01% 1456
2019
Q2 		$9.84M Buy
1,086,893
+274,745
+34% +$4.1M ﹤0.01% 1318
2019
Q1 		$19.4M Buy
812,148
+1,300
+0.2% +$26.6K ﹤0.01% 1179
2018
Q4 		$13.3M Buy
810,848
+1,468
+0.2% +$28.9K ﹤0.01% 1257
2018
Q3 		$21.5M Buy
809,380
+134,677
+20% +$3.05M ﹤0.01% 1207
2018
Q2 		$15.4M Buy
674,703
+196,094
+41% +$4.28M ﹤0.01% 1272
2018
Q1 		$10.2M Buy
478,609
+432,113
+929% +$6.58M ﹤0.01% 1329
2017
Q4 		$588K Buy
+46,496
New +$623K ﹤0.01% 2031

Other funds holding MYOV

HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

T. Rowe Price Associates's MYOV Position: Q1 2023 in Review

T. Rowe Price Associates sold out of Myovant Sciences Ltd. (MYOV) in Q1 2023, closing a stake of 10,900 shares — an estimated $294K sold.

T. Rowe Price Associates first reported a position in MYOV in Q4 2017 and held it in 13 quarters. The position peaked at $21.5M in Q3 2018. 2 funds tracked by Wall St. Rank hold MYOV as of Q1 2023.

  • T. Rowe Price Associates reported no remaining Myovant Sciences Ltd. position as of Q1 2023 after selling out during the quarter.
  • T. Rowe Price Associates sold 10,900 Myovant Sciences Ltd. shares in Q1 2023, an estimated $294K.
  • T. Rowe Price Associates first reported a position in Myovant Sciences Ltd. in Q4 2017 and held it in 13 quarters.
  • T. Rowe Price Associates's Myovant Sciences Ltd. position peaked at $21.5M in Q3 2018.
  • 2 funds tracked by Wall St. Rank held Myovant Sciences Ltd. as of Q1 2023.

Based on T. Rowe Price Associates's 13F filing for Q1 2023, filed 15 May 2023.